Combating Illicit Xylazine Act
HB1266, the Combating Illicit Xylazine Act, would place xylazine into Schedule III of the federal Controlled Substances Act and define the substance in federal law, including its salts and isomers. The bill is aimed at restricting illicit use and diversion of xylazine while preserving legitimate veterinary and animal-related uses. It creates a special definition of “ultimate user” for xylazine so that possession is limited to people who obtained it through a veterinarian or veterinarian-authorized pharmacy for specified animal-related purposes, including household animals, animals under care, government animal-control programs, and wildlife programs.
The bill also phases in certain regulatory requirements and directs federal agencies to help manufacturers and practitioners transition to the new scheduling status. It delays some labeling, packaging, distribution, registration, inventory, and recordkeeping requirements for specified periods after enactment, and it exempts existing manufacturers from having to make immediate capital expenditures to meet Schedule III security standards. In addition, it requires the DEA to track xylazine through ARCOS, directs the Sentencing Commission to consider penalties for xylazine-related offenses, and mandates two reports to Congress on illicit use, diversion, origin, trafficking, misuse, and possible analogues.
If enacted, the bill would amend the Controlled Substances Act to add xylazine to Schedule III and to create xylazine-specific rules for lawful possession, veterinary dispensing, and federal tracking. It would affect manufacturers, veterinarians, pharmacies, animal-control agencies, wildlife programs, and law enforcement by imposing controlled-substance compliance obligations while preserving animal-use access. The bill would also prompt related updates to DEA reporting systems and federal sentencing guidance, and it would require HHS/FDA and DEA coordination on implementation.
The available context suggests generally favorable bipartisan sentiment. The bill was introduced by a large bipartisan group of House members and was forwarded by subcommittee to the full committee by voice vote, indicating broad procedural support and little visible opposition at that stage. The absence of recorded votes or committee transcript debate suggests the measure was not highly contentious in the available record.
The main policy tension in the bill is between restricting illicit xylazine use and avoiding disruption to legitimate veterinary and animal-related uses. Potential points of concern include the burden of Schedule III compliance on manufacturers, pharmacies, and practitioners, the delayed effective dates for certain requirements, and whether federal scheduling could affect access for veterinary medicine, animal-control operations, and wildlife management. The bill’s reporting requirements also reflect concern about diversion, origin, and possible xylazine analogues, signaling ongoing uncertainty about the scope of the problem and the appropriate enforcement response.